HIV

RegulatoryJuly 13, 2026

FDA Submission for Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate

The FDA has received a new drug application (NDA219804) for a combination therapy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate from Aspen SA Operations.

Companies

Assets

Recent signals(25)

FDA Submission Overview for Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate

Study on Multimorbidity and Polypharmacy in HIV Patients in Basque Country

FDA Accepts NDA for IDVYNSO Containing Doravirine and Islatravir

NIAID Study on HIV Pathogenesis Using Human Blood Cells

Merck's Access Plans for Alimatravir in HIV PrEP Targeting Low-Income Countries

Study on HIV-1 Replication During Long-term Antiretroviral Therapy Initiated

Islatravir and Lenacapavir Show Sustained Virologic Suppression in Phase 3 HIV Trials

Phase 1 Trial of mRNA HIV Vaccines DV700P-RNA and DV701B1.1-RNA Initiated

FDA Approves Supplement for Biktarvy by Gilead Sciences

GSK's Bepirovirsen Study Targets HIV/HBV Co-Infection Efficacy and Safety

ViiV Healthcare initiates first-in-human trial for antiretroviral VH4770359

Merck to Present New Data on HIV Treatment Options at AIDS 2026

Study on Behavioral Economics to Enhance ART Adherence in HIV Patients

Long-Term Study on Cabotegravir Plus Rilpivirine Effectiveness in HIV Patients

FDA Submission for Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate

Study on Herpesvirus Reactivation in HIV-Infected Women Initiating ART

FDA Accepts NDA for IDVYNSO Containing Doravirine and Islatravir

ViiV Healthcare Compares Two-Drug vs Three-Drug Regimen in HIV Treatment Study

Merck Partners with ADAP to Enhance Access to IDVYNSO for HIV Treatment

Study Evaluates HIV Treatment Strategies for Opioid Users in Malaysia

Study on Patient Navigation Models for HIV Treatment in Criminal Justice Populations

ViiV Healthcare's CAB ULA and RPV ULA Study for Virologically Suppressed HIV Patients

Study on Intestinal TRM Cells and HIV-1 Persistence During ART Launched

FDA Approves Merck’s IDVYNSO for Virologically Suppressed HIV-1 Patients

Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir

Upcoming catalysts

Indications

Get signals before the market moves